PremiumThe FlySAB Biotherapeutics held cash and equivalents of $20.8 million at end of 2024 Biotech Alert: Searches spiking for these stocks today SAB Biotherapeutics announces data from Phase 1 trial of SAB-142 PremiumThe FlySAB Biotherapeutics provides SAB-142 clinical trial progress update SAB Biotherapeutics initiated with an Outperform at Oppenheimer SAB Biotherapeutics founds Clinical Advisory Board for SAB-142 development PremiumThe FlySAB Biotherapeutics initiated with Buy on risk/reward at Brookline SAB Biotherapeutics initiated with a Buy at Brookline SAB Biotherapeutics Appoints Mr. Conley, Details Public Disclosure 
